Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds

#	Paper	IF	Citations
344	Novel cyclohexanone compound as a potential ligand against SARS-CoV-2 main-protease. **2020**, 149, 104546		20
343	Potential therapeutic effect of turmeric contents against SARS-CoV-2 compared with experimental COVID-19 therapies: in silico study. **2020**, 1-14		16
342	Using Chou's 5-steps rule to study pharmacophore-based virtual screening of SARS-CoV-2 Mpro inhibitors. **2021**, 25, 1731-1744		4
341	Molecular basis of COVID-19 pathogenesis. **2020**, 89, 858-878		11
340	Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects. **2020**, 33, 108254		107
339	Investigating Potential Inhibitory Effect of (Cat's Claw) against the Main Protease 3CL of SARS-CoV-2 by Molecular Modeling. **2020**, 2020, 4932572		16
338	Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface. **2020**, 89, 107372		16
337	In silico exploration of small-molecule α-helix mimetics as inhibitors of SARS-COV-2 attachment to ACE2. **2020**, 1-12		3
336	Virtual screening, molecular dynamics and structure-activity relationship studies to identify potent approved drugs for Covid-19 treatment. **2021**, 39, 6231-6241		32
335	Consensus virtual screening of dark chemical matter and food chemicals uncover potential inhibitors of SARS-CoV-2 main protease.. **2020**, 10, 25089-25099		15
334	Computational discovery of small drug-like compounds as potential inhibitors of SARS-CoV-2 main protease. **2021**, 39, 5779-5791		14
333	SARS-CoV and SARS-CoV-2 main protease residue interaction networks change when bound to inhibitor N3. **2020**, 211, 107575		12
332	Learning from history: do not flatten the curve of antiviral research!. **2020**, 25, 1604-1613		10
331	Artificial Intelligence (AI) and Big Data for Coronavirus (COVID-19) Pandemic: A Survey on the State-of-the-Arts. **2020**, 8, 130820-130839		107
330	In silico molecular docking and molecular dynamic simulation of potential inhibitors of 3C-like main proteinase (3CLpro) from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) using selected african medicinal plants. **2020**, 1		7
329	Structure-based identification of potential SARS-CoV-2 main protease inhibitors. **2020**, 1-14		35
328	Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site. **2020**, 11, 5877		60

327 A new prediction approach of the COVID-19 virus pandemic behavior with a hybrid ensemble modular nonlinear autoregressive neural network. **2020**, 1-10   4

326 COVID-19: Advances in diagnostic tools, treatment strategies, and vaccine development. **2020**, 45, 1   24

325 Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease. **2020**, 1-12   12

324 In-silico drug repurposing for targeting SARS-CoV-2 main protease (M). **2020**, 1-8   14

323 In Silico Discovery of Antimicrobial Peptides as an Alternative to Control SARS-CoV-2. **2020**, 25,   8

322 A program to automate the discovery of drugs for West Nile and Dengue virus-programmatic screening of over a billion compounds on PubChem, generation of drug leads and automated modelling. **2020**, 1-9   3

321 Interactive Molecular Dynamics in Virtual Reality Is an Effective Tool for Flexible Substrate and Inhibitor Docking to the SARS-CoV-2 Main Protease. **2020**, 60, 5803-5814   16

320 Dissecting the Drug Development Strategies Against SARS-CoV-2 Through Diverse Computational Modeling Techniques. **2020**, 329   4

319 Coronavirus diseases 2019: Current biological situation and potential therapeutic perspective. **2020**, 886, 173447   20

318 Genomics insights of SARS-CoV-2 (COVID-19) into target-based drug discovery. **2020**, 29, 1-15   21

317 Repurposing Low-Molecular-Weight Drugs against the Main Protease of Severe Acute Respiratory Syndrome Coronavirus 2. **2020**, 11, 7267-7272   16

316 The Use of Methods of Computer-Aided Drug Discovery in the Development of Topoisomerase II Inhibitors: Applications and Future Directions. **2020**, 60, 3703-3721   10

315 High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2. **2020**, 25,   47

314 COVID-19 and SARS-CoV-2. Modeling the present, looking at the future. **2020**, 869, 1-51   90

313 In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. **2020**, 56, 106119   24

312 Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design. **2020**, 88, 107351   40

311 Potential Therapeutic Agents and Associated Bioassay Data for COVID-19 and Related Human Coronavirus Infections. **2020**, 3, 813-834   17

310 Systemic Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server. **2020**, 60, 5735-5745   14

309	Protein reliability analysis and virtual screening of natural inhibitors for SARS-CoV-2 main protease (M) through docking, molecular mechanic & dynamic, and ADMET profiling. **2021**, 39, 6810-6827	11
308	The Current Recommended Drugs and Strategies for the Treatment of Coronavirus Disease (COVID-19). **2020**, 16, 933-946	4
307	Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches. **2020**, 19, 4291-4315	36
306	Stopping the COVID-19 Pandemic: A Review on the Advances of Diagnosis, Treatment, and Control Measures. **2020**, 2020, 9121429	10
305	SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. **2020**, 19, 40	62
304	Drug repurposing approach to fight COVID-19. **2020**, 72, 1479-1508	165
303	Computer-Aided Analysis of Multiple SARS-CoV-2 Therapeutic Targets: Identification of Potent Molecules from African Medicinal Plants. **2020**, 2020, 1878410	5
302	An overview of COVID-19 with an emphasis on computational approach for its preventive intervention. **2020**, 10, 435	9
301	Identification of potential inhibitors of SARS-CoV-2 main protease and spike receptor from 10 important spices through structure-based virtual screening and molecular dynamic study. **2020**, 1-22	23
300	Impact of Early Pandemic Stage Mutations on Molecular Dynamics of SARS-CoV-2 M. **2020**, 60, 5080-5102	38
299	Ligand and structure-based virtual screening applied to the SARS-CoV-2 main protease: an repurposing study. **2020**, 12, 1815-1828	51
298	Artificial Intelligence for COVID-19 Drug Discovery and Vaccine Development. **2020**, 3, 65	80
297	Putative SARS-CoV-2 M Inhibitors from an In-House Library of Natural and Nature-Inspired Products: A Virtual Screening and Molecular Docking Study. **2020**, 25,	21
296	Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease. **2020**, 8,	61
295	Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19. **2020**, 7, 616341	38
294	Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2. **2020**, 8, 590263	12
293	COVID-19, microthromboses, inflammation, and platelet activating factor. **2020**, 46, 927-933	25
292	Supercomputer-Based Ensemble Docking Drug Discovery Pipeline with Application to Covid-19. **2020**, 60, 5832-5852	71

273	Possible SARS-coronavirus 2 inhibitor revealed by simulated molecular docking to viral main protease and host toll-like receptor. **2020**, 15, 359-368		29
272	Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19. **2021**, 25, 1665-1677		27
271	Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS-CoV2: An In Silico Analysis. **2020**, 10,		33
270	Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors. **2020**, 88, 107325		47
269	Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design. **2020**, 21,		93
268	On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges. **2020**, 10,		76
267	Origin, Potential Therapeutic Targets and Treatment for Coronavirus Disease (COVID-19). **2020**, 9,		40
266	COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. **2020**, 46, 306-308		67
265	D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19. **2020**, 10, 1239-1248		41
264	Boosting the arsenal against COVID-19 through computational drug repurposing. **2020**, 25, 946-948		38
263	Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies. **2021**, 78, 1501-1522		56
262	Insights on 3D Structures of Potential Drug-targeting Proteins of SARS-CoV-2: Application of Cavity Search and Molecular Docking. *Molecular Informatics*, **2021**, 40, e2000096	3.8	7
261	Potential influence of Nagella sativa (Black cumin) in reinforcing immune system: A hope to decelerate the COVID-19 pandemic. **2021**, 85, 153277		28
260	Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors. **2021**, 29, 115860		58
259	A review of COVID-19 biomarkers and drug targets: resources and tools. **2021**, 22, 701-713		12
258	Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review. **2021**, 106, 104490		52
257	Potential inhibitors of SARS-CoV-2: recent advances. **2021**, 29, 349-364		7
256	Potential SARS-CoV-2 main protease inhibitors. **2021**, 26, 804-816		52

237 Harnessing the Capability of CADD Methods in the Prediction of Anti-COVID Drug Likeliness. **2021**, 269-287

236 Contribution of machine learning approaches in response to SARS-CoV-2 infection. **2021**, 23, 100526   13

235 Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study. **2021**, 52, 38-47   25

234 Artificial intelligence-driven drug repurposing and structural biology for SARS-CoV-2. **2021**, 2, 100042   1

233 Computational Determination of Potential Multiprotein Targeting Natural Compounds for Rational Drug Design Against SARS-COV-2. **2021**, 26,   16

232 SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development. **2021**, 14, 225-238   10

231 Targeting allosteric pockets of SARS-CoV-2 main protease M. **2021**, 1-16   4

230 A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening. **2021**, 24, 102021   18

229 Advances in de Novo Drug Design: From Conventional to Machine Learning Methods. **2021**, 22,   28

228 Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases. **2021**, 288, 5089-5121   13

227 New Insights Into Potential Benefits of Bioactive Compounds of Bee Products on COVID-19: A Review and Assessment of Recent Research. **2020**, 7, 618318   6

226 Phytochemicals of spp. as Potential Inhibitors of the SARS-CoV-2 Main Protease: Molecular Docking and Drug-Likeness Study. **2021**, 2021, 8814890   5

225 Promising phytochemicals of traditional Indian herbal steam inhalation therapy to combat COVID-19 - An in silico study. **2021**, 148, 111966   17

224 Docking and toxicity assessment of compounds as potential antiviral agents against SARS-CoV-2. **2021**, 33, 1-24   12

223 Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies. **2021**, 1-13   7

222 A Blueprint for High Affinity SARS-CoV-2 Mpro Inhibitors from Activity-Based Compound Library Screening Guided by Analysis of Protein Dynamics. **2021**, 4, 1079-1095   15

221 Potential inhibitors interacting in Neuropilin-1 to develop an adjuvant drug against COVID-19, by molecular docking. **2021**, 33, 116040   10

220 High-throughput virtual laboratory for drug discovery using massive datasets. **2021**, 35, 452-468   2

219	Virtual Screening and Molecular Design of Potential SARS-COV-2 Inhibitors. **2021**, 76, 95-113	0
218	Artificial Intelligence-Aided Precision Medicine for COVID-19: Strategic Areas of Research and Development. **2021**, 23, e22453	8
217	drug designing for COVID-19: an approach of high-throughput virtual screening, molecular, and essential dynamics simulations. **2021**, 1-15	1
216	Dieckol and Its Derivatives as Potential Inhibitors of SARS-CoV-2 Spike Protein (UK Strain: VUI 202012/01): A Computational Study. **2021**, 19,	7
215	Drug repurposing to face Covid-19: Celastrol, a potential leading drug capable of inhibiting SARS-CoV-2 replication and induced inflammation.	
214	Computational Simulations Identified Marine-Derived Natural Bioactive Compounds as Replication Inhibitors of SARS-CoV-2. **2021**, 12, 647295	12
213	Detection of COVID-19 Disease in Chest X-Ray Images with capsul networks: application with cloud computing. 1-15	0
212	Potential drug targets of SARS-CoV-2: From genomics to therapeutics. **2021**, 177, 1-9	34
211	Investigation of angucycline compounds as potential drug candidates against SARS Cov-2 main protease using docking and molecular dynamic approaches. **2021**, 1	2
210	Docking Paradigm in Drug Design. **2021**, 21, 507-546	7
209	Structural dynamics of the coronavirus Mpro protease ligand binding sites.	2
208	Novel 1,2,3-Triazole Derivatives as Potential Inhibitors against Covid-19 Main Protease: Synthesis, Characterization, Molecular Docking and DFT Studies. **2021**, 6, 3468-3486	12
207	Modeling the binding of protoporphyrin IX, verteporfin, and chlorin e6 to SARS-CoV-2 proteins. **2021**, 57, 1-9	5
206	COVID-19 Impacts, Diagnosis and Possible Therapeutic Techniques: A Comprehensive Review. **2021**, 27, 1170-1184	8
205	Can nutraceuticals assist treatment and improve covid-19 symptoms?. **2021**, 1-20	15
204	Rational design of potent anti-COVID-19 main protease drugs: An extensive multi-spectrum in silico approach. **2021**, 330, 115636	4
203	Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19. **2021**, 24, 716-728	22
202	The application of in silico experimental model in the assessment of ciprofloxacin and levofloxacin interaction with main SARS-CoV-2 targets: S-, E- and TMPRSS2 proteins, RNA-dependent RNA polymerase and papain-like protease (PLpro)-preliminary molecular docking analysis. **2021**, 73, 1765-1780	1

201	Target SARS-CoV-2: theoretical exploration on clinical suitability of certain drugs. **2021**, 1-8		0
200	Molecular dynamics analysis of N-acetyl-D-glucosamine against specific SARS-CoV-2's pathogenicity factors. **2021**, 16, e0252571		1
199	In silico Studies on the Interaction between Mpro and PLpro From SARS-CoV-2 and Ebselen, its Metabolites and Derivatives. *Molecular Informatics*, **2021**, 40, e2100028	3.8	15
198	Benchmarking the Ability of Common Docking Programs to Correctly Reproduce and Score Binding Modes in SARS-CoV-2 Protease Mpro. **2021**, 61, 2957-2966		13
197	Drug combination therapy for emerging viral diseases. **2021**, 26, 2367-2376		11
196	A hybrid in silico approach reveals novel inhibitors of multiple SARS-CoV-2 variants.		
195	Docking-based virtual screening studies aiming at the covalent inhibition of SARS-CoV-2 M by targeting the cysteine 145. **2021**, 92, 107463		3
194	Identification of non-covalent SARS-CoV-2 main protease inhibitors by a virtual screen of commercially available drug-like compounds. **2021**, 41, 127990		
193	A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2. **2021**, 22,		5
192	Dynamic Profiling of ⊠Coronavirus 3CL M Protease Ligand-Binding Sites. **2021**, 61, 3058-3073		9
191	ssRNA Aptamers against the SARS-CoV-2 Main Protease: In Silico Design and Molecular Dynamics Simulation. **2021**, 22,		3
190	Plant-Based Phytochemical Screening by Targeting Main Protease of SARS-CoV-2 to Design Effective Potent Inhibitors. **2021**, 10,		18
189	New insights into the catalytic mechanism of the SARS-CoV-2 main protease: an ONIOM QM/MM approach. **2021**, 1		4
188	SARS-CoV-2 and its new variants: a comprehensive review on nanotechnological application insights into potential approaches. **2021**, 1-29		2
187	Advances in the computational landscape for repurposed drugs against COVID-19. **2021**, 26, 2800-2815		4
186	Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics. **2021**, 189, 114424		17
185	Rhizomes as a Natural Source of SARS-CoV-2 Mpro Inhibitors-Molecular Docking and In Vitro Study. **2021**, 14,		10
184	Strengths and Weaknesses of Docking Simulations in the SARS-CoV-2 Era: the Main Protease (Mpro) Case Study. **2021**, 61, 3758-3770		10

183	A machine learning regression model for the screening and design of potential SARS-CoV-2 protease inhibitors. **2021**, 10, 51	5
182	Drug repurposing combined with MM/PBSA based validation strategies towards MEK inhibitors screening. **2021**, 1-12	0
181	Accurate Estimation of Solvent Accessible Surface Area for Coarse-Grained Biomolecular Structures with Deep Learning. **2021**, 125, 9490-9498	0
180	Ensembling machine learning models to boost molecular affinity prediction. **2021**, 93, 107529	3
179	Near-physiological-temperature serial crystallography reveals conformations of SARS-CoV-2 main protease active site for improved drug repurposing. **2021**, 29, 1382-1396.e6	6
178	Identification of known drugs as potential SARS-CoV-2 Mpro inhibitors using ligand- and structure-based virtual screening. **2021**, 13, 1353-1366	5
177	Structural investigation of tetrahydropteridin analogues as selective PLK1 inhibitors for treating cancer through combined QSAR techniques, molecular docking, and molecular dynamics simulations. **2021**, 335, 116235	9
176	The identification of novel inhibitors of human angiotensin-converting enzyme 2 and main protease of Sars-Cov-2: A combination of methods for treatment of COVID-19. **2021**, 1237, 130409	4
175	Recent omics-based computational methods for COVID-19 drug discovery and repurposing. **2021**, 22,	3
174	Molecular Docking Analysis of the Phytochemicals from Tinospora Cordifolia as Potential Inhibitor Against Multi Targeted SARS-CoV-2 & Cytokine Storm. **2021**, 20, 559-580	0
173	Design and Evaluation of Bispidine-Based SARS-CoV-2 Main Protease Inhibitors.	2
172	Antiviral peptides against the main protease of SARS-CoV-2: A molecular docking and dynamics study.. **2021**, 14, 103315	12
171	Identifying compounds that prevent the binding of the SARS-CoV-2 S-protein to ACE2. **2021**, 136, 104719	1
170	Artificial Intelligence for COVID-19: A Systematic Review. **2021**, 8, 704256	7
169	The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance. **2021**, 1, 15	1
168	New 1,2,3-Triazole Scaffold Schiff Bases as Potential Anti-COVID-19: Design, Synthesis, DFT-Molecular Docking, and Cytotoxicity Aspects. **2021**, 9,	5
167	Design of ZnO-Drug Nanocarriers against the Main Protease of SARS-CoV-2 (COVID-19): An In Silico Assay. **2021**, 2, 257-266	0
166	Structural Understanding of SARS-CoV-2 Drug Targets, Active Site Contour Map Analysis and COVID-19 Therapeutics. **2021**,	3

| 129 | Blocking Effect of Demethylzeylasteral on the Interaction between Human ACE2 Protein and SARS-CoV-2 RBD Protein Discovered Using SPR Technology. **2020**, 26, | 10 |

| 128 | An overview of potential therapeutic agents to treat COVID-19. **2020**, 14, 318-327 | 4 |

| 127 | Potential COVID-19 papain-like protease PL inhibitors: repurposing FDA-approved drugs. **2020**, 8, e9965 | 30 |

| 126 | High predictive QSAR models for predicting the SARS coronavirus main protease inhibition activity of ketone-based covalent inhibitors. 1 | 0 |

| 125 | Michaelis-like complex of SARS-CoV-2 main protease visualized by room-temperature X-ray crystallography. **2021**, 8, 973-979 | 5 |

| 124 | Evaluation of SARS-CoV-2 main protease and inhibitor interactions using dihedral angle distributions and radial distribution function. **2021**, 7, e08220 | 1 |

| 123 | Tomatidine and Patchouli Alcohol as Inhibitors of SARS-CoV-2 Enzymes (3CLpro, PLpro and NSP15) by Molecular Docking and Molecular Dynamics Simulations. **2021**, 22, | 12 |

| 122 | De novo design of novel protease inhibitor candidates in the treatment of SARS-CoV-2 using deep learning, docking, and molecular dynamic simulations. **2021**, 139, 104967 | 19 |

| 121 | DINC-COVID: A webserver for ensemble docking with flexible SARS-CoV-2 proteins. **2021**, 139, 104943 | 0 |

| 120 | The Omic Insights on Unfolding Saga of COVID-19. **2021**, 12, 724914 | 0 |

| 119 | Repurposing low molecular-weight drugs against the main protease of severe acute respiratory syndrome coronavirus 2. | |

| 118 | A Transferable Deep Learning Approach to Fast Screen Potent Antiviral Drugs against SARS-CoV-2. | |

| 117 | Role of Machine Learning Techniques to Tackle the COVID-19 Crisis: Systematic Review (Preprint). | |

| 116 | Natural Products-Based Drug Design against SARS-CoV-2 Mpro 3CLpro. **2021**, 22, | 7 |

| 115 | Structural, Electronic, and Electrostatic Determinants for Inhibitor Binding to Subsites S1 and S2 in SARS-CoV-2 Main Protease. **2021**, 64, 17366-17383 | 7 |

| 114 | Deep Learning Driven Drug Discovery: Tackling Severe Acute Respiratory Syndrome Coronavirus 2. **2021**, 12, 739684 | 6 |

| 113 | Identification of low micromolar SARS-CoV-2 Mpro inhibitors from hits identified by in silico screens. | 2 |

| 112 | Theoretical insights into the effect of halogenated substituent on the electronic structure and spectroscopic properties of the favipiravir tautomeric forms and its implications for the treatment of COVID-19.. **2021**, 11, 35228-35244 | 0 |

93	Binding mechanism of inhibitors to SARS-CoV-2 main protease deciphered by multiple replica molecular dynamics simulations.. **2022**,	6
92	Artificial intelligence-enabled virtual screening of ultra-large chemical libraries with deep docking.. **2022**,	10
91	Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses.. **2022**,	16
90	Investigating Novel Thiazolyl-Indazole Derivatives as Scaffolds for SARS-Cov-2 MPro Inhibitors. **2022**, 4, 100034	
89	Contribution of Deep-Learning Techniques Toward Fighting COVID-19: A Bibliometric Analysis of Scholarly Production During 2020.. **2022**, 10, 33281-33300	1
88	Pyrido[1,2-]purine: Design and Synthesis of Appropriate Inhibitory Candidates against the Main Protease of COVID-19.. **2022**,	1
87	Complex machine learning model needs complex testing: Examining predictability of molecular binding affinity by a graph neural network.. **2022**,	1
86	Non-covalent SARS-CoV-2 M inhibitors developed from in silico screen hits.. **2022**, 12, 2505	4
85	Targeting two potential sites of SARS-CoV-2 main protease through computational drug repurposing.. **2022**, 1-11	1
84	A Novel Deep Neural Network Technique for Drug-Target Interaction.. **2022**, 14,	0
83	Artificial Intelligence Technologies for COVID-19 De Novo Drug Design.. **2022**, 23,	1
82	Systematic Tracing of Susceptible Animals to SARS-CoV-2 by a Bioinformatics Framework.. **2022**, 13, 781770	0
81	Molecular insights to the binding interactions of APNS containing HIV-protease inhibitors against SARS-CoV-2 M: an approach towards drug repurposing.. **2022**, 1-14	0
80	Perceiving SARS-CoV-2 Mpro and PLpro dual inhibitors from pool of recognized antiviral compounds of endophytic microbes: an in silico simulation study.. **2022**, 1-25	2
79	Identification of potential antivirals against 3CLpro enzyme for the treatment of SARS-CoV-2: A multi-step virtual screening study.. **2022**, 1-30	0
78	Machine learning prediction of 3CL SARS-CoV-2 docking scores.. **2022**, 98, 107656	0
77	The Role of Molecular Modeling and Bioinformatics in Treating a Pandemic Disease: The Case of COVID-19. **2021**, 1, 216-234	0
76	A Comparison between Enrichment Optimization Algorithm (EOA)-Based and Docking-Based Virtual Screening.. **2021**, 23,	0

57	Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2.	7
56	Targeting SARS-CoV-2 non-structural protein 13 via helicase-inhibitor-repurposing and non-structural protein 16 through pharmacophore-based screening.	1
55	When virtual screening yields to inactive drugs dealing with false theoretical-friends.	0
54	Natural products as a therapy to combat against SARS-CoV-2 virus infection. **2022**, 115-145	
53	Landscape determinants of infectivity and insights into vaccine development and effectiveness ฀ Novel Coronavirus. **2022**, 19,	
52	Therapeutic role of traditionally used Indian medicinal plants and spices in combating COVID-19 pandemic situation. 1-20	0
51	Allosteric hotspots in the main protease of SARS-CoV-2. **2022**, 167748	0
50	An agent-based transmission model of COVID-19 for re-opening policy design. **2022**, 105847	0
49	A comprehensive review of artificial intelligence and network based approaches to drug repurposing in Covid-19. **2022**, 153, 113350	2
48	Virtual screening of substances used in the treatment of SARS-CoV-2 infection and analysis of compounds with known action on structurally similar proteins from other viruses. **2022**, 153, 113432	1
47	Portability for GPU-accelerated molecular docking applications for cloud and HPC: can portable compiler directives provide performance across all platforms?. **2022**,	0
46	Is the reductionist paradox an Achilles Heel of drug discovery?. **2022**, 36, 329-338	
45	Viral informatics: bioinformatics-based solution for managing viral infections.	1
44	QFFT quantum circuits for exact solutions of the black-hole singularity-mass schrฟinger equations on quantum kerr- (A) ds galilean myers฀berr driven gravitational transformations in a lorentzian path integral for the anti-COVID-19 roccuffirnatm, roccuttirnaTM, and eplerotiffirnaTM drug designs. **2022**, 9,	0
43	Antiviral potential of diminazene aceturate against SARS-CoV-2 proteases using computational and in vitro approaches. **2022**, 367, 110161	2
42	Deep learning-based molecular dynamics simulation for structure-based drug design against SARS-CoV-2. **2022**, 20, 5014-5027	0
41	Multicriteria group decision making via generalized trapezoidal intuitionistic fuzzy number-based novel similarity measure and its application to diverse COVID-19 scenarios.	0
40	Adsorption of Selected Molecules on (TiO2)20 Nano-Clusters: A Density-Functional-Theory Study. **2022**, 2, 124-145	1

39	A computational insight on the inhibitory potential of 8-Hydroxydihydrosanguinarine (8-HDS), a pyridone containing analogue of sanguinarine, against SARS CoV2..	1
38	Pelargonium sidoides Root Extract: Simultaneous HPLC Separation, Determination, and Validation of Selected Biomolecules and Evaluation of SARS-CoV2 Inhibitory Activity. **2022**, 15, 1184	0
37	Visible Light-Promoted Green and Sustainable Approach for One-Pot Synthesis of 4,4ʹ(Arylmethylene)bis(1H-pyrazol-5-ols), In Vitro Anticancer Activity, and Molecular Docking with Covid-19 Mpro. **2022**, 7, 34583-34598	0
36	Generation of new inhibitors of selected cytochrome P450 subtypesⁿn silico study. **2022**,	0
35	Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CLpro. **2022**, 207, 105419	0
34	Computational Modeling of Protease Inhibitors for the Development of Drugs Against Coronaviruses. **2021**, 473-493	0
33	Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer. **2022**, 12, 1590	0
32	Deep learning in drug discovery: a futuristic modality to materialize the large datasets for cheminformatics. 1-16	0
31	Screening, Docking, and Molecular Dynamics Study of Natural Compounds as an Anti-HER2 for the Management of Breast Cancer. **2022**, 12, 1729	0
30	Structure and Computational Studies of New Sulfonamide Compound: {(4-nitrophenyl)sulfonyl}tryptophan. **2022**, 27, 7400	0
29	Using filters in virtual screening: A comprehensive guide to minimize errors and maximize efficiency. **2022**,	0
28	Characterizing the ligand-binding affinity to SARS-CoV-2 Mpro via physics and knowledge based approaches.	0
27	In silico evaluation of the inhibitory potential of nucleocapsid inhibitors of SARS-CoV-2: a binding and energetic perspective. 1-11	1
26	Review of Developments in Combating COVID-19 by Vaccines, Inhibitors, Radiations, and Nonthermal Plasma. **2022**, 44, 5666-5690	1
25	Progress on COVID-19 Chemotherapeutics Discovery and Novel Technology. **2022**, 27, 8257	1
24	Pathfinder-Driven Chemical Space Exploration and Multiparameter Optimization in Tandem with Glide/IFD and QSAR-Based Active Learning Approach to Prioritize Design Ideas for FEP+ Calculations of SARS-CoV-2 PLpro Inhibitors. **2022**, 27, 8569	0
23	Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CLpro. **2022**, 23, 16011	1
22	Surely you are joking, Mr Docking!.	1

21	Pyridine derivatives complexes of Co (II) and Ni (II) 3-Bromobenzoates: Crystal Structure, in silico Anti-SARS-CoV-2 potential, Serum Albumin Binding Properties and Cytotoxicity.	0
20	Multi-ligand molecular docking, simulation, free energy calculations and wavelet analysis of the synergistic effects between natural compounds baicalein and cubebin for the inhibition of the main protease of SARS-CoV-2. **2023**, 121253	0
19	Paving New Roads Using Allium sativum as a Repurposed Drug and Analyzing its Antiviral Action Using Artificial Intelligence Technology. **2023**, 21,	0
18	Natural product inhibitors as potential drug candidates against Alzheimer's disease: Structural-based drug design, molecular docking, molecular dynamic simulation experiments, and ADMET predictions. **2023**, 100, 100977	0
17	Advances in the discovery of new chemotypes through ultra-large library docking. **2023**, 18, 303-313	0
16	Discovery of Isojacareubin as a covalent inhibitor of SARS-CoV-2 main protease using structural and experimental approaches. **2023**, 95,	0
15	AI-accelerated protein-ligand docking for SARS-CoV-2 is 100-fold faster with no significant change in detection. **2023**, 13,	0
14	Role of SARS-CoV-2 Spike-Protein-Induced Activation of Microglia and Mast Cells in the Pathogenesis of Neuro-COVID. **2023**, 12, 688	1
13	Artificial Intelligence, Machine Learning, and Big Data for Ebola Virus Drug Discovery. **2023**, 16, 332	0
12	Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. **2023**, 24, 4401	0
11	Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery Genetics Alliance Perspective. **2023**, 66, 3664-3702	0
10	Advances and critical assessment of machine learning techniques for prediction of docking scores.	0
9	Synthesis, molecular docking and dynamics studies of pyridazino[4,5-b]quinoxalin-1(2H)-ones as targeting main protease of COVID-19. 1-13	0
8	Chemical Space Virtual Screening against Hard-to-Drug RNA Methyltransferases DNMT2 and NSUN6. **2023**, 24, 6109	0
7	SARS-CoV2 billion-compound docking. **2023**, 10,	0
6	Discovery of Potential Inhibitors of SARS-CoV-2 Main Protease by a Transfer Learning Method. **2023**, 15, 891	0
5	Outpatient medications associated with protection from COVID-19 hospitalization. **2023**, 18, e0282961	0
4	The Impact of Supervised Learning Methods in Ultralarge High-Throughput Docking.	0

3	The role of machine learning in health policies during the COVID-19 pandemic and in long COVID management. 11,	0
2	In-silico approaches for identification of compounds inhibiting SARS-CoV-2 3CL protease. **2023**, 18, e0284301	0
1	Computational approaches streamlining drug discovery. **2023**, 616, 673-685	0